From 01 April 2020 to 31 March 2021, the MHRA’s Good Pharmacovigilance Practice Inspectorate (GPvP) conducted 37 pharmacovigilance (PV) inspections on 36 marketing authorisation holders (MAHs) to evaluate its PV processes and compliance with existing EU and national PV regulations.
Read MoreUtilisation of artificial intelligence (AI) to transform key steps in clinical trials to increase clinical trial efficiency, improve patient safety and the patient experience.
Read MoreA pharmacovigilance perspective on the Cumberlege Report…
Read MoreThe evolution of patient registries for pharmacovigilance.
Read MoreA look at four areas where contingency plans are urgently needed to Brexit-proof your PV system.
Read More